Download Files:
TA-02
SKU
HY-100115-10 mg
Category Reference compound
Tags Autophagy;MAPK/ERK Pathway, Autophagy;p38 MAPK, Cancer; Inflammation/Immunology; Cardiovascular Disease
$70 – $520
Products Details
Product Description
– TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295)[1].
Web ID
– HY-100115
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C20H13F2N3
References
– [1]Laco F, et al. Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling. J Mol Cell Cardiol. 2015 Mar;80:56-70.|[2]Jiedong Liang, et al. The activation of BDNF reduced inflammation in a spinal cord injury model by TrkB/p38 MAPK signaling. Exp Ther Med. 2019 Mar;17(3):1688-1696.
CAS Number
– 1784751-19-4
Molecular Weight
– 333.33
Compound Purity
– 99.57
SMILES
– FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)NC(C4=CC=CC=C4F)=N2
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology; Cardiovascular Disease
Solubility
– DMSO : 25 mg/mL (ultrasonic)
Target
– Autophagy;p38 MAPK
Pathway
– Autophagy;MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.